The Medicinal Chemistry of Imidazotetrazine Prodrugs
AbstractTemozolomide (TMZ) is the standard first line treatment for malignant glioma, reaching “blockbuster” status in 2010, yet it remains the only drug in its class. The main constraints on the clinical effectiveness of TMZ therapy are its requirement for active DNA mismatch repair (MMR) proteins for activity, and inherent resistance through O6-methyl guanine-DNA methyl transferase (MGMT) activity. Moreover, acquired resistance, due to MMR mutation, results in aggressive TMZ-resistant tumour regrowth following good initial responses. Much of the attraction in TMZ as a drug lies in its PK/PD properties: it is acid stable and has 100% oral bioavailability; it also has excellent distribution properties, crosses the blood-brain barrier, and there is direct evidence of tumour localisation. This review seeks to unravel some of the mysteries of the imidazotetrazine class of compounds to which TMZ belongs. In addition to an overview of different synthetic strategies, we explore the somewhat unusual chemical reactivity of the imidazotetrazines, probing their mechanisms of reaction, examining which attributes are required for an active drug molecule and reviewing the use of this combined knowledge towards the development of new and improved anti-cancer agents. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Moody, C.L.; Wheelhouse, R.T. The Medicinal Chemistry of Imidazotetrazine Prodrugs. Pharmaceuticals 2014, 7, 797-838.
Moody CL, Wheelhouse RT. The Medicinal Chemistry of Imidazotetrazine Prodrugs. Pharmaceuticals. 2014; 7(7):797-838.Chicago/Turabian Style
Moody, Catherine L.; Wheelhouse, Richard T. 2014. "The Medicinal Chemistry of Imidazotetrazine Prodrugs." Pharmaceuticals 7, no. 7: 797-838.